Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for global professionals · Friday, March 29, 2024 · 699,693,299 Articles · 3+ Million Readers

Invokana® Ketoacidosis, Lower Limb Amputations, Kidney Damage Claims Now Under Review with Personal Injury Law Firms

Glen Lerner Injury Attorneys & Lerner and Rowe Injury Attorneys announced they are now accepting Invokana® serious injury class action claims for review.

Our attorneys are prepared to speak up for anyone who may have been harmed by Invokana® or other SGLT2 inhibitor drugs and to even the odds in a courtroom if need be.”
— Glen Lerner, ESQ.

LAS VEGAS, NV, UNITED STATES, December 23, 2017 /EINPresswire.com/ -- In response to recent allegations of harm (Judicial Panel on Multidistrict Litigation reports 952 actions pending regarding Invokana® products liability litigation as of 12/18/2017), the personal injury law firms of Glen Lerner Injury Attorneys and Lerner and Rowe Injury Attorneys announced they are now accepting Invokana® diabetic ketoacidosis, lower limb amputation, and kidney damage claims for review. These allegations claim that Janssen Pharmaceuticals, Inc. (Janssen) failed to adequately test the drug and warn of its risk.

Invokana® (generic name: canagliflozin) was manufactured by Janssen, a division of Johnson & Johnson, and was the first SGLT2 inhibitor approved for sale in the U.S. in March of 2013. (source: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=204042)

Since then these other SGLT2 inhibitor diabetes drug have also been brought to the market:

● Invokamet® (canagliflozin/metformin)
● Farxiga® (dapagliflozin)
● Xigduo XR® (dapagliflozin/metformin)
● Jardiance® (empagliflozin)
● Glyxambi® (empagliflozin/linagliptin)

In September of 2015, the FDA approved the publication of a post-marketing study that Janssen was ordered to conduct when Invokana® was first approved for sell. At the same time, updated warning labels were added to Invokana® and Invokamet® based on finding from that study to include information about decreased bone mineral density and bone fracture risk. (source: https://www.fda.gov/downloads/drugs/drugsafety/ucm461790.pdf)

Eight months after those label were updated, the FDA added another warning about SGLT2 kidney side effects based on more than 100 submitted adverse event reports. (source: https://www.fda.gov/Drugs/DrugSafety/DrugSafetyPodcasts/ucm507785.htm)

In May of 2017, the FDA announced that Invokana® would be required to add a black box warning to any marketing materials regarding risks of amputation to patients. (source: https://www.fda.gov/drugs/drugsafety/ucm557507.htm)

“It is unfortunate that these SGLT2 inhibitor drugs were originally prescribed and marketed to Type 2 Diabetes patients to help control their condition and now are allegedly being linked to hospitalization for serious side effects related to heart, kidney and liver injuries and just recently amputation of toes, feet and legs,” said Personal Injury Attorney Glen Lerner. “Our attorneys are prepared to speak up for anyone who may have been harmed by Invokana® or other SGLT2 inhibitor drugs and to even the odds in a courtroom if need be.”

Invokana® diabetic ketoacidosis, amputation, kidney injury, heart disease or other related serious injury class action claim reviews may be submitted to the personal injury law firms Glen Lerner Injury Attorneys or Lerner and Rowe Injury Attorneys by calling 952-200-3129, or by submitting an online case review form at glenlerner.com or at lernerandrowe.com/invokana-lawsuit/. People that have been harmed after taking Invokana® diabetic to treat your Type 2 Diabetes, you may be entitled to compensation for damages.

About Glen Lerner Injury Attorneys

Glen Lerner Injury Attorneys began helping people with personal injury and dangerous drugs claims in Nevada 25 years ago. Over the past two decades, Glen Lerner Injury Attorneys has grown into one of the largest plaintiff’s personal injury law firms in the country, with over 40 attorneys and nearly three hundred employees located in Nevada, Arizona, California, Washington, Illinois and Indiana. The Glen Lerner attorneys also have relationships and associations with attorneys across the country to help those hurt outside of states where the firm practices. The firm also assists with social security claims and dangerous product lawsuits nationally, and represents criminal defense cases in Arizona.

Follow the law firm on Twitter (twitter.com/glenlerner) and like their Facebook page (facebook.com/glenlernerinjuryattorneys) for current updates regarding legal topics and their community involvement and contributions.

More About Lerner and Rowe

For additional information about Lerner and Rowe’s Phoenix personal injury attorneys call (602) 977-1900. To learn more about the criminal defense and bankruptcy legal services offered by their partner law firm Lerner and Rowe Law Group, visit lernerandrowelawgroup.com or call (602) 667-7777. Need help filing an application or appeal for Social Security benefits? Contact the law firms other legal partners at Social Security Disability Advocates by calling (602) 952-3200 or online at socialsecuritydisabilityadvocatesusa.com.

To connect with the law firm socially, follow Lerner and Rowe on Twitter, or become a fan of their Facebook page. Also visit lernerandrowegivesback.com to learn more about the community services that the lawyers and legal support team of Lerner and Rowe actively support.

###


Sources:

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=204042

Jim Rolshouse
Glen Lerner Injury Attorneys/Lerner & Rowe Injury Attorneys
952-200-3129
email us here

Powered by EIN Presswire


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release